Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS

In the ARTEMIS trial, 689 treatment-naïve, HIV-1-infected adults received darunavir/ritonavir (DRV/r) 800/100 mg every day or lopinavir/ritonavir (LPV/r) 800/200 mg total daily dose plus fixed-dose tenofovir/emtricitabine. Week 96 metabolic parameters are reported. Adverse events (AEs) classed as me...

Full description

Saved in:
Bibliographic Details
Published in:International journal of STD & AIDS 2013-01, Vol.24 (1), p.12-17
Main Authors: Arathoon, E, Schneider, S, Baraldi, E, Lim, P L, Opravil, M, Van De Casteele, T, Lavreys, L
Format: Article
Language:English
Subjects:
Adult
AIDS/HIV
CD4 Lymphocyte Count
Darunavir
Drug Administration Schedule
Drug Therapy, Combination
Drug-Related Side Effects and Adverse Reactions - metabolism
Female
HIV Infections - drug therapy
HIV Infections - virology
HIV Protease Inhibitors - administration & dosage
HIV Protease Inhibitors - adverse effects
HIV-1 - drug effects
Humans
Lopinavir - administration & dosage
Lopinavir - adverse effects
Male
Middle Aged
Ritonavir - administration & dosage
Ritonavir - adverse effects
RNA, Viral - blood
Sulfonamides - administration & dosage
Sulfonamides - adverse effects
Treatment Outcome
Viral Load
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the ARTEMIS trial, 689 treatment-naïve, HIV-1-infected adults received darunavir/ritonavir (DRV/r) 800/100 mg every day or lopinavir/ritonavir (LPV/r) 800/200 mg total daily dose plus fixed-dose tenofovir/emtricitabine. Week 96 metabolic parameters are reported. Adverse events (AEs) classed as metabolism/nutrition disorders were observed in 14% of DRV/r and 22% of LPV/r patients. Lipid-related AEs were reported in fewer DRV/r (8%) than LPV/r (16%) patients. A small increase in glucose and insulin levels was observed at week 96 in both groups. Lipoma was the only lipodystrophy-related AE reported in >1% of patients (DRV/r, n = 1; LPV/r, n = 4) and no grade 3 or 4 lipodystrophy-related AEs were reported. No clinically relevant changes from baseline were seen in anthropometric measurements in either group. Median mid-waist/hip ratio at week 96 was comparable to baseline in both arms. Over 96 weeks, DRV/r had a similar effect on glucose and insulin levels but a more favourable lipid profile than LPV/r in treatment-naïve, HIV-infected patients.
ISSN:0956-4624
1758-1052
DOI:10.1258/ijsa.2012.012120